How Obesity Impacts Psoriatic Arthritis Treatment Response

"How Obesity Impacts Psoriatic Arthritis Treatment Response" takes up the question of why weight and joint disease are so tightly linked.

Dr. Perkins explains that obesity is deeply intertwined with psoriatic arthritis. While some autoimmune conditions cause weight loss, psoriatic arthritis tends to bring weight gain, and she cites data showing 60% to 75% of patients with psoriatic disease also live with obesity. That overlap creates a heavy burden. Patients battle joint and skin disease while also facing obesity's own complications. Many, like Kameillia, feel they are doing everything right yet still not seeing results. Dr. Perkins notes that even the best available biologics often fail to deliver full remission in patients with obesity. That pushed her to ask what else could change Kameillia's outcome once she had already tried the best drugs on the market. She addresses weight-based dosing directly. As BMI rises, she explains, many drugs become measurably less effective, a pattern documented repeatedly in the literature. Some medications can be dosed by weight to compensate, while others use fixed dosing regardless of size. Understanding this interplay between obesity and inflammation matters for treatment selection. She points to studies showing patients with obesity have less than half the likelihood of reaching remission on the same medication as patients without it. That raises the question of whether weight itself is modifiable enough to improve treatment response. Dr. Perkins says rheumatologists have long faced frustration here. Older weight-loss options, mainly lifestyle changes and early oral medications, topped out around a 5% reduction, even in highly motivated patients doing everything asked of them. She describes the arrival of incretin-class drugs, originally used for diabetes, as a turning point. It was discovered almost by accident, when patients on these medications for other reasons began showing unexpected improvement in their rheumatologic disease. Weight loss with this class now approaches levels once seen only with bariatric surgery.

Kameillia describes how her weight fluctuated constantly as her disease progressed, gaining 10 pounds, losing 5, then gaining 15 more in an unpredictable cycle. She and Dr. Perkins discussed her weight at nearly every visit, tracking where things stood. Kameillia says she was doing what she was told: exercising, working with a trainer, trying an appetite suppressant a different doctor prescribed, and following Mediterranean-style meals. None of it mattered consistently. Her weight would either stay flat or continue climbing regardless of effort. She says the physical burden compounded the mental one. Managing chronic pain while trying to stay active and avoid depression felt like layers of difficulty stacking on top of each other, both mentally and physically exhausting.

Dr. Perkins details the association between weight and improvement in psoriatic arthritis. She cites a study that found a significant jump in minimal disease activity with just a 5% body weight loss. She contrasts that with the higher weight loss that is now achievable with newer drugs.

Our next episode, " Adding an Incretin Therapy to a Biologic for PsA: TOGETHER-PsA Trial," experts talk about TOGETHER-PsA trial and what convinced Kameillia to try combination therapy.